References

emcardio

Неотложная кардиология и кардиоваскулярные риски

Emergency Cardiology and Cardiovascular Risks journal

2616-633X

Белорусский государственный медицинский университет

emcardio-296

Research Article

Мастер-класс

Master-class

Кардиогенный шок при остром инфаркте миокарда - потери и достижения

Cardiogenic Shock in Acute Myocardial Infarction - Losses and Achievements

Митьковская

Н. П.

Mitkovskaya

N. P.

УО «Белорусский государственный медицинский университет»Belarusian State Medical University

2017

15112025

11620

2025

Митьковская Н.П.

Mitkovskaya N.P.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://emcardio.bsmu.by/jour/article/view/296

Тяжелейшее проявление острой сердечной недостаточности - кардиогенный шок (КШ) встречается у 7-8% пациентов и сопровождается неблагоприятными исходами в 40-60% случаев, оставаясь основной причиной смерти среди пациентов, госпитализированных с острым инфарктом миокарда, особенно у пациентов с эпизодами остановки кровообращения. Североамериканский регистр INTERMACS, созданный для анализа эффективности применения различных систем оказания помощи пациентам с тяжелой сердечной недостаточностью, в том числе систем вспомогательного кровообращения, классифицирует КШ как INTERMACS1.

The most severe manifestation of acute cardiac failure - cardiogenic shock (CS)-occurs in 5-7% of patients and is accompanied by unfavorable outcome in 40-60% of cases, thus remaining the main cause of death among patients admitted to hospital with acute myocardial infarction. The North- American register INTERMACS, created for analyzing the effectiveness of application of various systems for rendering assistance to patients with severe cardiac failure, including the systems of artificial circulatory support, classifies cardiogenic shock as INTEMACS1.

инфаркт миокардакардиогенный шоклетальностьфармакологическая и механическая поддержка

myocardial infarctioncardiogenic shockmortalitypharmacological and mechanical support

References1

HoedemakerN. P.G., ten Haaf M. E., Maas J. C., Damman P., Appelman Y., Tijssen J. G.P., de Winter R. J., van 'tHof A.W.J. Practice of ST-segment elevation myocardial infarction care in the Netherlands during four snapshot weeks with the National Cardiovascular Database Registry for Acute Coronary Syndrome. Neth Heart J, 2017, vol. 25, pp. 264-270.

Krishnan U., Brejt J. A., Schulman-Marcus J., Rajesh V. Swaminathan, Feldman D. N., ChiuWong S., Goyal P., Horn E. M., Karas M., Sobol I., Minutello R. M., G. Bergman, Singh H., Kim L. K. Characteristics of hospitalizations for cardiogenic shock after acute myocardial infarction in the United States. IntJ Cardiol, 2017, vol. 244, pp. 213-219.

Jhund P. S., McMurray J. J. Heart failure after acute myocardial infarction: a lost battle in the war on heart failure? Circulation, 2008, vol. 118, no 20, pp.2019-2021.

Ibanez B., James S., Agewall S., Antunes M. J., Bucciarelli-Ducci C., Bueno H., Caforio A. L.P., Crea F., Goudevenos J. A., Halvorsen S., Hindricks G., Kastrati A., Lenzen M. J., Prescott E., Roffi M., Valgimigli M., Varenhorst C., Vranckx P., Widimsky P. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2017, vol. 26. doi: 10.1093/eurheartj/ehx393.

Reynolds H. R., Hochman J. S. Cardiogenic shock: current concepts and improving outcomes. Circulation, 2008. vol. 117, no 5, pp.686-697.

Kelly D. J., Gershlick T., Witzenbichler B., Guagliumi G., Fahy M., Dangas G., Mehran R., Stone G. W. Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. Am Heart J. 2011, vol.162, no.4, pp. 663-670.

Yancy C. W., Jessup M., Bozkurt B., Butler J., Casey D. E. Jr, Drazner M. H., Fonarow G. C., Geraci S. A., Horwich T., Januzzi J. L. [et al.] 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation, 2013, vol. 128, no.16, pp. 240-327.

Poss J., Koster J., Fuernau G., Eitel I., de Waha S., Ouarrak T., Lassus J., Harjola V. P., Zeymer U., Thiele H., Desch S. Risk Stratification for Patient in Cardiogenic Shock After Acute Myocardial Infarction. J Am Coll Cardiol. 2017, vol. 69, no. 15, pp.1913-1920.

Pinto D. S., Grandin E. W. Risk Prediction in AMI Shock. Goldilocks and the Search for «Just Right». JACC. 2017, vol. 69, no. 15, pp.1921-1923.

McAlindon E., Bucciarelli-Ducci C., Suleiman M. S., Baumbach A. Infarct size reduction in acute myocardial infarction. Heart, 2015, vol.101, no. 2, pp.155-160.

Thiele H., Ohman E. M., Desch S., Eitel I, de Waha S. Management of cardiogenic shock. Eur Heart J. 2015, vol. 36, no. 20, pp. 1223-1230.

Prondzinsky R. Unverzagt S., Lemm H. Wegener N. A., Schlitt A., Heinroth K. M., Dietz S., Buerke U., Kellner P., Loppnow H., Fiedler M. G., Thiery J., Werdan K., Buerke M. Interleukin-6,-7,-8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock. Clin Res Cardiol. 2012, vol. 101, no.5, pp. 375-384.

Reynolds H. R., Hochman J. S. Cardiogenic shock: current concepts and improving outcomes. Circulation, 2008. vol. 117, no. 5, pp.686-697.

Morrow A. D. Myocardial infarction. A companion to Braunvald's Heart Disease. Elsevier, 2017, 467p.

Grimaldi D., Sauneuf B., Guivarch E., Ricome S., Geri G., Charpentier J., Zuber B., Dumas, Spaulding C., Mira J. P., Cariou A. High level of endotoxemia following out-of-hospital cardiac arrest is associated with severity and duration of postcardiac arrest shock. Crit Care Med, 2015, vol. 43, no.12, pp. 2597-2604.

Mareev V. Yu., Arutyunov G. P., Astashkin E. I. Vertkin A. L., Glezer M. G., Lopatin Yu.M., Mazkeplishvili S. T., Mareev Yu.V., Sitnikova M. Yu., Fomin I.V9, Chirmanov V. N. Ostraya dekompensirovannaya serdechnaya nedostatochnost'. Soglasovannaya poziziya rossiyskich ekspertov [Acute decompensated heart failure. Consensus of Russian experts]. ZhurnalSerdechnaya Nedostatochnost'. 2014, vol. 15, no. 5(86), pp. 321-336. (in Russian).

Mit'kovskaya N.P., Toropilov D. M. Kardiorenal'nyy sindrom pri ostroy ishemicheskoy bolezni serdza [Cardiorenal syndrome in acute coronary heart disease]. Med. zhurnal, 2009, no. 1, pp. 19-23. (in Russian).

Statkevich, T.V., Mit'kovskaya N.P., Skugarevskiy O. A. Techenie infarkta miokarda u pazientov s metabolicheskim sindromom i razlichnym psichologicheskim statusom [The course of the course of myocardial infarction in patients with metabolic syndrome and various psychological status]. Kardiologiya v Belarusi, 2010, no. 6, pp. 36-47. (in Russian).

Thygesen K., Alpert J. S., Jaffe A. S. Simoons M. L., Chaitman B. R., White H. D. [et al.] Third universal definition of myocardial infarction. Circulation. 2012, vol. 126, no.16, pp. 2020-2035.

Shah N. R., Bieniarz M. C., Basra S. S., Paisley R.D., Loyalka P., Gregoric I. D., Mann D. L., Kar B. Serum biomarkers in severe refractory cardiogenic shock. JACC Heart Fail, 2013, vol. 1, no. 3, pp. 200-206.

Mit'kovskaya N.P., Abel'skaya I.S., Postoyalko A. S., Statkevich T. V., Galizkaya S. S., Smirnova E S., Balysh E. M., Samolyuk B. B. Prediktory neblagopriyatnych ischodov chreskozhnych koronarnych vmeshatel'stv u pazientov s ostrym infarktom miokarda s pod'emom segmenta ST [Predictors of adverse outcomes of percutaneous coronary interventions in patients with acute myocardial infarction with ST-segment elevation]. Med. panorama, 2012, no. 4, pp. 3-5. (in Russian).

Mit'kovskaya N.P., Abel'skaya I.S., Postoyalko A. S., Statkevich T. V., Galizkaya S. S., Balysh E. M., Smirnova E. S., Piskun B. B., Beymanov A. E., Gubar' E.N., Pavlovich O. V. Ostryy koronarnyy sindrom s pod'emom segmenta ST u pazientov s vysokim riskom rezidiviruyuschich koronarnych sobytiy [Acute coronary syndrome with ST-segment elevation in patients at high risk of recurrent coronary events]. Kardiologiya v Belarusi, 2013, no. 6, pp. 10-22. (in Russian).

Ivanova A. A., Maksimov V. N., Orlov P. S., Ivanoshchuk D. E., Savchenko S. V., Voevoda M. I. Association of the genetic markers for myocardial infarction with sudden cardiac death. Indian Heart Journal, 2017, vol. 69, pp. 8-11.

Mor-Avi V., Lang R. M., Badano L. P., Belohlavek M., Cardim N. M., Derumeaux G., Galderisi M., Marwick T., Nagueh S. F., Sengupta P. P, Sicari R., Smiseth O. A., Smulevitz B., Takeuchi M., Thomas J. D., Vannan M., Voigt J. U., Zamorano J. L. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/ EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiosr, 2011, vol.24, no.3, pp. 277-313.

Nagueh S. F., Rao L., Soto J., Middleton K. J., Khoury D. S. Haemodynamic insights into the effects of ischaemia and cycle length on tissue Doppler-derived mitral annulus diastolic velocities. Clin. Sci. (Lond.), 2004, vol. 106, no. 2, pp. 147-154.

Bokeriya O. L., Averina I. I. Klinicheskoe primenenie technologiy analiza funkzii miokarda. Ozenka gemodinamiki, markerov asimptomnoy disfunkzii, fibroza miokarda [Clinical application of technologies for the analysis of myocardial function. Assessment of hemodynamics, markers of asymptomatic dysfunction, myocardial fibrosis]. Byulleten' NZSSCh im. A. N. Bakuleva RAMN, 2014, vol. 15, no. 6, pp. 6-19. (in Russian).

Windecker S., Kolh P., Alfonso F., Collet J. P., Cremer J., Falk V., Filippatos G., Hamm C., Head S. J., Juni P., Kappetein A. P, Kastrati A., Knuuti J. [et al.] 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J, 2014, vol. 35, no. 37, pp. 2541-2619.

Hochman J. S., Sleeper L. A., Webb J. G., Dzavik V., Buller C. E., Aylward P., Col J., White H. D. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA, 2006, vol. 295, no. 21, pp. 2511-2515.

Kubler P., Reczuch K. Optimal stent treatment of cardiogenic shock complicating acute myocardial infarction: bare-metal or drug-eluting stent? Heart, 2017, vol. 103, no. 15, pp. 1146-1147.

Ledwoch J., Fuernau G., Desch St., Eitel I., Jung Ch., de Waha S., Poess J., Schneider St., Schuler G., Werdan K., Zeymer U., Thiele H. Drug-eluting stents versus bare-metal stents in acute myocardial infarction with cardiogenic shock. Heart, 2017, vol. 103, no. 15, pp. 1177-1184.

Singh K., Rashid M., So D. Y., Glover C. A., Froeschl M., Hibbert B., Chong A. Y., Dick A., Labinaz M., Le May M. Incidence, predictors, and clinical outcomes of early stent thrombosis in acute myocardial infarction patients treated with primary percutaneous coronary angioplasty (insights from the University of Ottawa Heart Institute STEMI registry). CatheterCardiovascInterv, 2017, pp.1-7. doi: 10.1002/ccd.27215.

Galizkaya S. S., Mit'kovskaya N.P., Abel'skaya I.S., Statkevich T. V., Postoyalko A. S., Gusina A. A., Sulimchik E. A. Ostryy koronarnyy sindrom s pod'emom segmenta ST: rezul'taty angiograficheskogo i geneticheskogo issledovaniy [Acute coronary syndrome with ST segment elevation: results of angiographic and genetic studies]. Veszi NAN Belarus/. Ser. med. navuk, 2015, no. 1, S. 21-26. (in Russian).

Kanic V., Vollrath M., Penko M., Markota A., Kompara G., Kanic Z. Lungand GPIIb-IIIa Receptor Inhibitors in Acute Coronary Syndrome Patients Presenting With Cardiogenic Shock and/or After Cardiopulmonary Resuscitation. Heart Lung Circ, 2017, vol. 20. doi: 10.1016/j.hlc.2017.02.011.

Tarantini G., D'Amico G., Tellaroli P., Colombo C., Brener S. J. Meta-Analysis of the Optimal Percutaneous Revascularization Strategy in Patients With Acute Myocardial Infarction, Cardiogenic Shock, and Multivessel Coronary Artery Disease. Am J Cardiol, 2017, vol. 119, no. 10, pp. 1525-1531.

Kalavrouziotis D., Dagenais F., Mohammadi S. Letter by Kalavrouziotis et al Regarding Article, «Temporal Trends in Predictors of Early and Late Mortality After Emergency Coronary Artery Bypass Grafting for Cardiogenic Shock Complicating Acute Myocardial Infarction». Circulatio, 2017, vol. 135, no. 13, pp. 814-815.

Gershlick A. H., Khan J. N., Kelly D. J., Greenwood J. P., Sasikaran T., Curzen N., Blackman D. J., Dalby M., Fairbrother K. L., Banya W., Wang D., Flather M., Hetherington S. L., Kelion A. D., Talwar S., Gunning M., Hall R., Swanton H., McCann G.P. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol. 2015, vol.65, no.10, pp.963-972.

Mylotte D., Morice M. C., Eltchaninoff H., Garot J., Louvard Y., LefevreT., Garot P. Primary percutaneous coronary intervention in patients with acute myocardial infarction, resuscitated cardiac arrest, and cardiogenic shock - the role of primary multivessel revascularization. JACC Cardiovasc Interv, 2013, vol. 6, no. 2, pp. 115-125.

Hussain F., Philipp R. K., Ducas R. A., Elliott J., Dzavik V., Jassal D. S., Tam J. W., Roberts D., Garber P. J., Ducas J. The ability to achieve complete revascularization is associated with improved in-hospital survival in cardiogenic shock due to myocardial infarction: Manitoba cardiogenic SHOCK Registry investigators. Catheter Cardiovasc Interv, 2011, vol. 78, no. 4, pp.540-548.

Kalavrouziotis D., Rodes-Cabau J. Mohammadi S. Moving Beyond SHOCK: New Paradigms in the Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock. Can J Cardiol, 2017, vol. 33, no. 1, pp. 36-43.

Quayyum Z., Briggs A., Robles-Zurita J., Oldroyd K., Zeymer U., Desch S., Waha S., Thiele H. Protocol for an economic evaluation of the randomised controlled trial of culprit lesion only PCI versus immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: CULPRIT-SHOCK trial. BMJOpen, 2017, vol. 18, no. 7(8). doi: 10.1136/ bmjopen-2016-014849.

Russo J. J. Goodman S. G., Cantor W. J., Tan M. K., Borgundvaag B., Fitchett D., Dzavik V., Yan R. T., Graham J. J., Mehta S. R., Yan A. T. Efficacy and safety of a routine early invasive strategy in relation to time from symptom onset to fibrinolysis (a subgroup analysis of TRANSFER-AMI). Am J Cardiol. 2015, vol. 115, no.8, pp. 1005-1012.

Teboul J. L., Radermacher P., Asfar P., High versus low blood-pressure target in septic shock. N Enel J Med, 2014, vol. 371, no. 3, pp. 283-284.

Tarvasmaki1 T., Lassus J., Varpula M., Sionis A., Sund R., K0ber L., Spinar J., Parissis J., Banaszewski M., Cardoso S. J., Carubelli V., Di Somma S., Mebazaa A. Veli-Pekka Harjola1 and for the CardShock study investigators. Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenalin use is associated with excess organ injur and mortality. Critical Care, 2016, vol. 20. doi: 10.1186/s13054-016-1387-1.

Levy B., Perez P., Perny J., Thivilier C., Gerard A. Comparison of norepinephrine dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med, 2011, vol. 39, no. 3, pp.450-455.

Francis G. S., Bartos J. A., Adatya S. Inotropes. J Am Coll Cardiol, 2014, vol. no. 63, pp. 2069-2078.

Unverzagt S., Wachsmuth L., Hirsch K., Thiele H., Buerke M., Haerting J., Werdan K., Prondzinsky R. Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev, 2014, vol.2, no. 1. doi: 10.1002/14651858.CD009669.

Pirracchio R., Parenica J., Resche Rigon M., Chevret S., Spinar J., Jarkovsky J., Zannad F., Alla F., Mebazaa A. The effectiveness of inodilators in reducing short term mortality among patient with severe cardiogenic shock: a propensity-based analysis. PLoS One. 2013, vol. 8, no. 8, pp. 716-759.

Overgaard C. B., Dzavik V. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation, 2008, vol. 118, no. 10, pp. 1047-1056.

Hongisto M., Lassus J., Tarvasmaki T., Sionis A., Tolppanen H., Lindholm M. G., Banaszewski M., Parissis J., Spinar J., Silva-Cardoso J., Carubelli V., Di Somma S., Masip J., Harjola V. P. Use of noninvasive and invasive mechanical ventilation in cardiogenic shock: A prospective multicenter study. Int J Cardiol, 2017, vol. 230, pp. 191-197.

Nativi-Nicolau J., Selzman C. H., Fang J. C., Stehlik J. Pharmacologic therapies for acute cardiogenic shock. Curr Opin Cardiol, 2014, vol. 29, no. 3, pp. 250-257.

Akchurin R. S., Tereschenko S. N., Zhirov I. V., Kosizyna I. V. Sistemy vspomogatel'nogo krovoobrascheniya v lechenii serdechnoy nedostatochnosti [Systems of ancillary circulation in the treatment of heart failure]. Kardiologiya, 2010, vol. 50, no. 9, pp. 51-56. (in Russian).

Torii R., Sotomi Y., Collet C., Dijkstra J., Miyazaki Y., Crake T., Su S., Costa R., Chamie D., Liew H.- B., Santoso T., Onuma Y., Abizaid A., Bourantas Ch.V., Serruys P. W. A Meta¬Analysis Early Initiation of Impella in Acute Myocardial Infarction Complicated by Cardiogenic Shock Improves Survival Erhan Tenekecioglu. JACC: Cardiovasc IntervSvol. 2017, vol. 10, no. 17, pp. 1803-1806.

George G. W. Vetrovec Hemodynamic Support Devices for Shock and High-Risk PCI: When and Which One. Curr Cardiol Rep. 2017, vol. 19 no.10, pp. 100. doi: 10.1007/s11886-017- 0905-3.

Kazui T., Tran P. L., Pilikian T. R., Marsh K. M., Runyan R., Konhilas J., Smith R., Khalpey Z. A dual therapy of off-pump temporary left ventricular extracorporeal device and amniotic stem cell for cardiogenic shock. J CardiothoracSurg, 2017, vol. 12, no. 1, pp. 80. doi: 10.1186/s13019-017-0648-7.

The authors declare that there are no conflicts of interest present.